Aethlon Medical announced it will issue third quarter results for the fiscal year ended March 31, 2018 at 4:15 pm ET on Thursday, February 1, 2018. Management will host a conference call on Thursday, February 1, 2018 at 4:30 pm ET to review financial results and corporate highlights. To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and international callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical Inc., conference call. The conference call will also be available through a live webcast on the Company website. For additional information, read today's press release:

The San Diego Union Tribune reports on Aethlon Medical's testing of the Hemopurifier to capture exosomes associated with the spread of cancer. The article highlights Aethlon's recent National Cancer Institute award to study both non-malignant exosomes and oncosomes with the goal to see if the Hemopurifier can be used as an accessory to cancer immunotherapy. The article also details the Hemopurifier's ability to remove viruses from the blood and the Company's work in CTE. Read the full feature here:

Aethlon Medical announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 ("the '418 Application"), entitled "METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS." The allowed claims of the '418 Application embody cartridges for the Aethlon Hemopurifier®, which removes viral particles from the blood or plasma of infected patients. The '418 Application is a continuation of U.S. Patent Number 7,226,429, which embodies methods of reducing viral loads in the blood of individuals infected with a virus. Together, this intellectual property further protects the Aethlon Hemopurifier® and secures Aethlon's position as a leader in pioneering therapeutic strategies to address viral infections. Read the entire release:

Aethlon announced the appointment of Sabrina Martucci Johnson to its Board of Directors and to its Audit Committee. Ms. Johnson qualifies as an independent director under the Nasdaq Rules. "We are very pleased to have Sabrina join the Aethlon team," stated Aethlon Medical founder and CEO, Jim Joyce. "With the recent "Breakthrough Device" designation of our Hemopurifier, Sabrina's appointment reflects our focus to build a Board of Directors with relevant experience in transitioning clinical-stage therapies to the marketplace." For more information, read today's press release:

CNN highlights the threat of bioterrorism and how biological weapons, if used, will spread quickly, have a widespread impact and be undetected until a pandemic stage is suddenly upon us. Experts such as Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), and Dr. Gerald W. Parker, Jr., director of Texas A&M University's Pandemic and Biosecurity Policy Program, warn that we are not prepared to deal with these threats and there is a need for government programs for successful counter-measures.

Aethlon today announced the appointment of Charles (“Chuck”) J. Fisher, Jr., MD as Chairman of its Board of Directors. “We are truly appreciative that Chuck has agreed to expand his role within our organization,” stated Aethlon founder & CEO Jim Joyce. “His leadership in advancing first-in- class therapies to market will no doubt contribute to our mission to commercialize our Hemopurifier® and other life-saving therapeutic candidates.” For full details, read today's press release:

BioWorld MedTech featured Aethlon and the unique market opportunity of the Hemopurifier as it has demonstrated the ability to capture a variety of pathogens such as multiple strains of influenza, Ebola, hepatitis c and Zika. The article highlights Aethlon's completed feasibility study, how the Hemopurifier works to capture pathogens and challenges the Company has faced in the development process.